This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Efficacy and Safety Study of SPL7013 Gel to Prevent the Recurrence of Bacterial Vaginosis (BV)

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
Starpharma Pty Ltd
ClinicalTrials.gov Identifier:
NCT02237950
First received: September 5, 2014
Last updated: October 13, 2016
Last verified: October 2016
  Purpose
A double-blind, phase 3 study to determine the efficacy of SPL7013 Gel when administered on alternate days for 16 weeks, compared to placebo gel in preventing the recurrence of BV in women with a history of recurrent BV.

Condition Intervention Phase
Bacterial Vaginosis Drug: Metronidazole oral tablets 500mg Drug: 1% SPL7013 Gel Drug: Placebo gel Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
Official Title: A Phase 3, Double-blind, Multicentre, Randomised, Placebo-controlled Study to Determine the Efficacy and Safety of SPL7013 Gel to Prevent the Recurrence of Bacterial Vaginosis

Resource links provided by NLM:


Further study details as provided by Starpharma Pty Ltd:

Primary Outcome Measures:
  • Recurrence of BV where a diagnosis of BV is defined as the presence of at least 3 clinical findings [ Time Frame: At or by the Week 16 visit ]
    Number of participants with a recurrence


Secondary Outcome Measures:
  • Time to recurrence of BV according to the primary efficacy endpoint definition [ Time Frame: At or by the Week 28 visit ]
    Time (days)

  • Presence of patient-reported BV symptoms [ Time Frame: At or by the Week 16 visit ]
    Number of participants with symptoms

  • Recurrence of individual Amsel criteria [ Time Frame: At or by the Week 16 visit ]

    Individual Amsel criteria are:

    i) Presence of homogenous vaginal discharge characteristic of BV ii) Positive whiff test iii) Clue cells representing at least 20% of total epithelial cells iv) vaginal fluid pH greater than 4.5


  • Recurrence of BV as determined by presence of a Nugent score of 7-10 [ Time Frame: At or by the Week 16 visit ]
    Number of participants with a recurrence

  • Recurrence of BV according to the primary efficacy endpoint definition [ Time Frame: At or by the Week 20, 24 and 28 visits ]
    Number of participants with a recurrence

  • Recurrence of BV according to the composite definition of at least 3 clinical findings and a Nugent score of at least 4 [ Time Frame: At or by the Week 16 visit ]
    Number of participants with a recurrence

  • Adverse events (AEs) [ Time Frame: Study duration ]
    Number of participants

  • Responses to Quality of Life (QoL) Questionnaires. [ Time Frame: Screening to Week 16 ]

Estimated Enrollment: 620
Study Start Date: September 2014
Estimated Primary Completion Date: January 2017 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1% SPL7013 Gel
Inserted in to the vagina on alternate days (i.e. every other day) for 16 weeks
Drug: Metronidazole oral tablets 500mg
One tablet taken orally twice daily for seven consecutive days
Drug: 1% SPL7013 Gel
5g inserted in to the vaginal on alternate days (i.e. every other day) for 16 consecutive weeks.
Other Names:
  • VivaGel
  • astodimer sodium
Placebo Comparator: Placebo Gel
Inserted in to the vagina on alternate days (i.e. every other day) for 16 weeks
Drug: Metronidazole oral tablets 500mg
One tablet taken orally twice daily for seven consecutive days
Drug: Placebo gel
5g inserted in to the vagina on alternate days (i.e. every other day) for 16 consecutive weeks

Detailed Description:

Eligible participants, with both a history of recurrent BV and a current episode of BV, will receive a seven-day course of oral metronidazole. Participants who are successfully treated for their BV, and continue to be eligible, will be randomly assigned to receive either 1% SPL7013 Gel or placebo gel on alternate days at bed-time for 16 consecutive weeks.

The primary endpoint will be determined at the conclusion of this 16 week treatment phase.

Participants who experience a BV recurrence will be considered to have completed the study. Such participants will receive BV treatment in line with local practice and will not attend any further study visits.

Participants who successfully reach Week 16 without a BV recurrence will enter a 12-week follow-up phase to Week 28.

Participants will attend a study visit at 4-weekly intervals throughout the duration of the study to Week 28 (or up to the point of BV recurrence) to assess recurrence of BV and adverse events.

  Eligibility

Ages Eligible for Study:   16 Years to 45 Years   (Child, Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Current active episode of BV (diagnosis defined as: At least 3 of the 4 Amsel criteria; Nugent score of at least 4; presence of BV-related symptoms)
  • History of recurrent BV (at least 3 episodes in previous year including current episode)
  • Using an effective method of contraception

Exclusion Criteria:

  • Test positive for a sexually transmitted infection
  • Presence of genital Herpes Simplex Virus (HSV) lesions or Human Papilloma Virus (HPV) lesions requiring treatment
  • Abnormal pelvic exam, including presence of other vaginal or urinary tract infections
  • Pregnancy
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT02237950

  Show 45 Study Locations
Sponsors and Collaborators
Starpharma Pty Ltd
Investigators
Study Chair: Jeremy Paull, PhD. Starpharma Pty Ltd
  More Information

Responsible Party: Starpharma Pty Ltd
ClinicalTrials.gov Identifier: NCT02237950     History of Changes
Other Study ID Numbers: SPL7013-017
Study First Received: September 5, 2014
Last Updated: October 13, 2016

Additional relevant MeSH terms:
Recurrence
Vaginal Diseases
Vaginosis, Bacterial
Disease Attributes
Pathologic Processes
Genital Diseases, Female
Bacterial Infections
Vaginitis
Metronidazole
Anti-Infective Agents
Antiprotozoal Agents
Antiparasitic Agents

ClinicalTrials.gov processed this record on August 16, 2017